PMN ProMIS Neurosciences Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1374339 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-32.5%
TTM EPS YoY62.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-152.3%
ROA-113.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets11.4%
Debt / equity0.00x
Current ratio8.83x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.07x
Accruals ratio7.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $33.38M | $10.64M | $7.88M | $16.09M | $4.63M |
| SG&A expense | $6.79M | $6.19M | $6.38M | $7.29M | $3.66M |
| Operating income | -$40.17M | -$16.83M | -$14.26M | -$23.38M | -$8.29M |
| Interest expense | — | — | — | $282,064 | $416,286 |
| Income tax | — | $0 | $0 | $0 | — |
| Net income | -$39.72M | $2.78M | -$13.21M | -$18.06M | -$9.79M |
| EBITDA | — | — | -$14.26M | -$23.37M | -$8.25M |
| EPS (basic) | -22.61 | 2.68 | -1.07 | -2.41 | -1.69 |
| EPS (diluted) | -22.61 | 2.63 | -1.07 | -2.41 | -1.69 |
| Weighted avg. shares (diluted) | 1.76M | 1.06M | 12.29M | 7.50M | 5.79M |
| Balance sheet | |||||
| Cash & equivalents | $6.12M | $13.29M | $12.60M | $5.88M | $16.94M |
| Short-term investments | $33,753 | $33,051 | $32,358 | $31,009 | $33,248 |
| Current assets | $9.18M | $18.91M | $13.62M | $6.90M | $17.71M |
| PP&E, net | — | — | — | $321 | $4,671 |
| Intangibles | — | — | — | $20,838 | $27,614 |
| Total assets | $9.18M | $18.91M | $13.62M | $6.92M | $17.75M |
| Current liabilities | $10.41M | $2.22M | $9.35M | $6.41M | $929,074 |
| Long-term debt | — | — | $0 | — | $3.91M |
| Total debt | — | — | $0 | — | $3.91M |
| Total liabilities | $10.44M | $2.42M | $9.87M | $8.27M | $12.09M |
| Shareholders' equity | -$1.26M | $16.49M | $3.75M | -$1.35M | $5.66M |
| Net debt | — | — | -$12.60M | — | -$13.04M |
| Shares outstanding | 2.15M | 1.31M | 18.89M | 8.58M | 7.20M |
| Cash flow statement | |||||
| Operating cash flow | -$28.12M | -$27.18M | -$10.84M | -$17.03M | -$9.31M |
| Capital expenditure | — | — | — | $1,981 | $6,044 |
| Free cash flow | — | — | — | -$17.04M | -$9.31M |
| Investing cash flow | -$702 | -$693 | -$1,349 | -$1,981 | $94,618 |
| Financing cash flow | $20.94M | $27.88M | $17.75M | $6.49M | $25.52M |
| Depreciation & amortization | — | — | $321 | $6,144 | $40,576 |
| Stock-based compensation | $857,628 | $825,808 | $271,542 | $487,630 | $515,629 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.